title: Cross-clade p17 peptide recognition by antisera to HGP-30, a 30-amino acid synthetic peptide antigen from HIV type 1 p17.
abstract: HGP-30, a 30-amino acid synthetic peptide analog of HIV-1SF2 p17 (aa 86-115), was used to immunize both mice and humans. Since the amino acid sequence of HGP-30 is relatively conserved among different HIV-1 strains and clades, experiments were carried out to determine if antisera obtained by immunizing animals and humans can recognize HGP-30-related peptide consensus sequences belonging to different clades. Results show that antisera from mice immunized with HGP-30 can recognize clade B and C and to a lesser degree clade A and E consensus sequences of HIV-1, in addition to recognizing HGP-30 sequence. The cross-clade recognition was higher in mouse sera obtained on day 42 than on day 14 or 28. MPL/SE and Novasomes were better adjuvants than alum in inducing antibodies that showed cross-clade recognition and IgG2a and IgG2b antibody isotypes. Similar cross-clade recognition was observed in several sera from humans immunized with an HGP-30/KLH/alum formulation. The human sera from HGP-30-immunized subjects evaluated for cross-clade recognition of HGP-30 peptides were from subjects whose cells showed significant protection from HIV infection on virus challenge in the hu-PBL-SCID mouse model. These studies suggest that HGP-30 may be useful as a candidate vaccine antigen for populations in countries with prevalence of different HIV clades.
authors.affiliation: CEL-SCI Corporation, Alexandria, Virginia 22314, USA.
authors.forename: D H
authors.initials: DH
authors.lastname: Zimmerman
authors.forename: J T
authors.initials: JT
authors.lastname: Ulrich
authors.forename: C
authors.initials: C
authors.lastname: Wright
authors.forename: J P
authors.initials: JP
authors.lastname: Lloyd
authors.forename: M D
authors.initials: MD
authors.lastname: Winship
authors.forename: P S
authors.initials: PS
authors.lastname: Sarin
mesh_terms: D016915:AIDS Vaccines / Q000276:immunology; D000276:Adjuvants, Immunologic; D000595:Amino Acid Sequence; D000818:Animals; D016384:Consensus Sequence; D003429:Cross Reactions; D004797:Enzyme-Linked Immunosorbent Assay; D000939:Epitopes / Q000276:immunology; D005260:Female; D015483:HIV Antibodies / Q000097:blood / Q000276:immunology*; D015488:HIV Antigens / Q000737:chemistry / Q000276:immunology*; D015497:HIV-1 / Q000145:classification / Q000276:immunology*; D006801:Humans; D007106:Immune Sera / Q000276:immunology; D007132:Immunoglobulin Isotypes; D051379:Mice; D008807:Mice, Inbred BALB C; D008969:Molecular Sequence Data; D010455:Peptides / Q000737:chemistry / Q000276:immunology*; D013997:Time Factors; D014611:Vaccination; D054301:gag Gene Products, Human Immunodeficiency Virus
chemical_list: D016915:AIDS Vaccines; D000276:Adjuvants, Immunologic; D000939:Epitopes; C052407:HGP-30 peptide, Human immunodeficiency virus-1; D015483:HIV Antibodies; D015488:HIV Antigens; D007106:Immune Sera; D007132:Immunoglobulin Isotypes; D010455:Peptides; D054301:gag Gene Products, Human Immunodeficiency Virus